, the family office of French entrepreneur Pierre-Edouard Stérin, founder of the SmartBox Group, is investing in Quantum Genomics’ new funding round in the amount of of €20M. The deal will help the company to advance its ongoing clinical research and strengthen its industrial production and commercial operations.Quantum
Genomics: biotech startup focused on cardiovascular drugsThe company, which is listed in the Euronext Growth Exchange in Paris, is specialized in the development of a new class of cardiovascular drugs acting directly on the brain to treat difficult-to-treat/resistant arterial hypertension and heart failure. ‘ goal is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Otium
Capital: leading French single family office in venture capitalPierre-Edouard Sterin, SmartBox’s founder and CEO, owns a very strong but diversified portfolio of investments in companies from the consumer goods, entertainment, tech, B2B, and healthcare industries through his family office Otium Capital. Also, some of Otium’s portfolio companies already successfully exited, standing out the one from , “one of the most successful startup exits in France by that time”.
Source: Picture
Source: Relevant family office articlesRelevant family office lists €199,99 including VAT Rated 4.67 out of 5 €499,99 including VAT Rated 4.67 out of 5 €1.499,99 including VAT €199,99 including VAT
User Comments1. Ava
Adams: Comment sample 1...2. Adams,
Benjamin: Comment sample 2...3. H.
Lewis: Comment sample 3...4. Parker, Mia: Comment sample 4...5. D.
Turner: Comment sample 5...Editor's NoteThis article was refined for clarity, structure, and user experience.
(Editors: admin)
Disclaimer & Copyright Notice:
This article is edited and compiled by the editorial team at WealthShield Asia based on publicly available information. It is intended for informational purposes only and does not constitute legal, financial, or investment advice.
We respect intellectual property rights. If you believe that any part of this article infringes upon your copyright or other legal rights, please contact us at
admin@wealthshield.asia. We will promptly review and remove the content if necessary.
All rights reserved. Unauthorized reproduction or redistribution is prohibited.
